3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
45
Precursor Cell Lymphoblastic Leukemia-Lymphoma
33
Myelodysplastic Syndromes
26
Recurrence
18
Multiple Myeloma
18
Lymphoma, Non-Hodgkin
15
Lymphoma, B-Cell
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Lymphoma
14
Ovarian Neoplasms
12
Hematologic Neoplasms
12
Pancreatic Neoplasms
10
Melanoma
10
Hodgkin Disease
10
Myeloproliferative Disorders
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Leukemia
9
Burkitt Lymphoma
9
Stomach Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
8
Neoplasms
7
Lymphoma, Mantle-Cell
7
Lymphoma, Follicular
7
Leukemia, Biphenotypic, Acute
7
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
6
Leukemia, Myelomonocytic, Juvenile
6
Leukemia, Myelomonocytic, Chronic
6
Breast Neoplasms
6
Interventions
Gemcitabine
29
pembrolizumab
21
Cisplatin
20
Specimen Handling
17
Magnetic Resonance Spectroscopy
17
enfortumab vedotin
10
Mitomycin
10
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
fludarabine
×
90 days
×
Clear all
NCT07492628
2026-03-25
DUET-UC-NK
Beijing Biotech
Phase 1
Recruiting
42 enrolled